| Literature DB >> 31484075 |
Rong Zhang1, James T Earnest2, Arthur S Kim3, Emma S Winkler4, Pritesh Desai2, Lucas J Adams2, Gaowei Hu1, Christopher Bullock4, Beth Gold5, Sara Cherry5, Michael S Diamond6.
Abstract
Mxra8 is a recently described receptor for multiple alphaviruses, including Chikungunya (CHIKV), Mayaro (MAYV), Ross River (RRV), and O'nyong nyong (ONNV) viruses. To determine its role in pathogenesis, we generated mice with mutant Mxra8 alleles: an 8-nucleotide deletion that produces a truncated, soluble form (Mxra8Δ8/Δ8) and a 97-nucleotide deletion that abolishes Mxra8 expression (Mxra8Δ97/Δ97). Mxra8Δ8/Δ8 and Mxra8Δ97/Δ97 fibroblasts show reduced CHIKV infection in culture, and Mxra8Δ8/Δ8 and Mxra8Δ97/Δ97 mice have decreased infection of musculoskeletal tissues with CHIKV, MAYV, RRV, or ONNV. Less foot swelling is observed in CHIKV-infected Mxra8 mutant mice, which correlated with fewer infiltrating neutrophils and cytokines. A recombinant E2-D71A CHIKV with diminished binding to Mxra8 is attenuated in vivo in wild-type mice. Ectopic Mxra8 expression is sufficient to enhance CHIKV infection and lethality in transgenic flies. These studies establish a role for Mxra8 in the pathogenesis of multiple alphaviruses and suggest that targeting this protein may mitigate disease in humans.Entities:
Keywords: alphavirus; arthritis; mice; pathogenesis; receptor
Mesh:
Substances:
Year: 2019 PMID: 31484075 PMCID: PMC6745702 DOI: 10.1016/j.celrep.2019.07.105
Source DB: PubMed Journal: Cell Rep Impact factor: 9.423
Figure 1.Generation of Mxra8-Deficient Mice by CRISPR-Cas9 Gene Targeting
(A) Scheme of Mxra8 gene locus with sgRNA targeting sites. Annotated transcripts are shown in gray and encoded proteins in purple. Two green arrows indicate the sgRNA targeting sites.
(B) Location of Mxra8 proteins (8- and 97-nt frameshift deletions) on the X-ray crystal structure of mouse Mxra8 (PDB: 6NK3). The structurally unsolved regions adjacent to the plasma membrane are shown as circled amino acids, and the ends of Mxra8 proteins generated by the gene-editing deletions are indicated by arrows. TM, transmembrane; tail, cytoplasmic domain.
(C and D) Western blotting of cell lysates (C) or culture supernatants (D) of primary MEFs from WT, Mxra8, and Mxra8 mice using two different anti-Mxra8 mAbs. Data are representative of two experiments.
(E) Growth kinetic analysis of CHIKV-AF15561 (MOI 0.01) in primary MEFs from WT, Mxra8, and Mxra8 mice. Data are pooled from two experiments (n = 6).
See also Figures S1 and S2.
Figure 2.CHIKV Infection in Mxra8-Deficient Mice during the Acute Phase after Subcutaneous Inoculation
(A and B) WT and Mxra8 mice were inoculated subcutaneously in the foot with 103 focus-forming units (FFU) of CHIKV-AF15561. (A) At 12 h post-infection, the ipsilateral ankle were harvested for virus titration by FFU assay (two experiments; n = 8; two-tailed Mann-Whitney test; **p < 0.01; ns, not significant). (B) At 1 and 2 dpi, serum was collected for viral RNA quantification by qRT-PCR (two experiments; n = 9–10; two-tailed Mann-Whitney test; *p < 0.05 and **p < 0.01).
(C–F) WT, Mxra8, or Mxra8 mice were inoculated subcutaneously in the foot with 103 FFU of CHIKV-AF15561. At 3 (C–E) or 7 dpi (F), foot swelling (C) was measured (two experiments; n = 8–18; one-way ANOVA with Tukey’s test; ***p < 0.001 and ****p < 0.0001), and ipsilateral and contralateral ankles and calf muscles (D–F) were harvested for virus titration by FFU assay (two experiments; n = 8–18; (D), one-way ANOVA with Tukey’s test; (E) Kruskal-Wallis with Dunn’s test; (F) two-tailed Mann-Whitney test; *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001; ns, not significant).
(G–L) WT and Mxra8 (G–I) or WT and Mxra8 (J–L) mice were inoculated subcutaneously in the foot with 103 FFU of CHIKV-AF15561 (G–I) or CHIKV-LR 2006 (J–L). At 3 dpi, foot swelling (G and J) was measured (two experiments; n = 9–12; two-tailed unpaired t test; ****p < 0.0001), and ipsilateral and contralateral ankles and calf muscles (H, I, K, and L) were harvested for virus titration by FFU assay (two experiments; n = 9–12; two-tailed Mann-Whitney test; *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001).
(M) RNA in situ hybridization of ipsilateral and contralateral feet using a CHIKV-specific probe from WT and Mxra8 mice at 3 dpi. CHIKV RNA+ foci in the contralateral ankles of WT mice are boxed and shown below as higher-magnification images. Scale bar, 100 βm; representative images are shown from n = 4 mice from two experiments.
See also Figure S3.
Figure 3.CHIKV Infection in Mxra8-Deficient Mice during the Acute Phase after Intravenous Inoculation
WT and Mxra8 mice were inoculated intravenously via the tail vein with 103 FFU of CHIKV-AF15561. At 1 and 3 dpi, ankle and calf muscle from both left (A) and right (B) sides were collected for virus titration by FFU assay (two experiments, n = 9–10; two-tailed Mann-Whitney test;**p <0.01, ***p < 0.001, and ****p < 0.0001; ns, not significant).
Figure 4.Diminished Infection of MAYV, RRV, and ONNV in Mxra8 Mice
WT and Mxra8 mice were inoculated subcutaneously in the foot with 103 FFU of MAYV (A–D), 103 FFU of RRV (E and F), or 103 FFU of ONNV (G). Foot swelling of MAYV infection (A) at 3 dpi was measured (two experiments; n = 14–15; two--tailed unpaired t test; ***p < 0.001). Ipsilateral and contralateral ankles and calf muscles at 12 h (G) and 3 dpi (B–F) were harvested for virus titration by FFU assay (two experiments; n = 9–15; two-tailed Mann-Whitney test; *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001; ns, not significant).
Figure 5.CHIKV Infection and Disease in Mxra8 Mice or WT Mice Treated with Blocking Anti-Mxra8 mAbs
(A and B) WT and Mxra8 mice were inoculated subcutaneously in the foot with 103 FFU of CHIKV-AF15561. (A) Foot swelling was measured daily for 28 days (two experiments; n = 11–13; means ± SEMs; two-way ANOVA with Sidak’s test; ****p < 0.0001). (B) Ipsilateral ankles were collected at 28 dpi, and viral RNA levels were measured by qRT-PCR (two experiments; n = 11–13; two-tailed Mann-Whitney test; ****p< 0.0001).
(C and D) WT mice were inoculated subcutaneously in the foot with 103 FFU of CHIKV-AF15561 and then administered either anti-Mxra8 mAbs (1G11.E6 + 7F1.D8; 300 μg total) or isotype control hamster mAb (300 μg) via an intraperitoneal injection at −12 h (C) or +12 h (D) post-infection. Subsequent doses of mAbs were administered at 4 and 8 dpi. Foot swelling was measured daily for 12 days (two experiments; n = 8; means ± SEMs; two-way ANOVA with Sidak’s test; *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001).
Figure 6.Analysis of Inflammation in the Musculoskeletal Tissues of Mxra8 Mice after CHIKV Infection
(A–D) WT and Mxra8 mice were inoculated subcutaneously in the foot with 103 FFU of CHIKV-AF15561.
(A) At 3 dpi, ipsilateral feet were collected, fixed, decalcified, paraffin embedded, sectioned, and stained with H&E. Scale bar, 100 μm; representative images are shown from n = 4 mice from two experiments. Arrows indicate tissue edema. At days 0 (B) (uninfected), 3 (C), and 7 (D) post-infection, cells from ipsilateral feet were harvested and analyzed for numbers of leukocytes (CD45+), monocytes (CD11b+CD11c−Ly6G−Ly6C+), neutrophils (CD11b+CD11c−Ly6G+), natural killer(NK) cells (CD3−NK1.1+), macrophages (CD11b+CD11c−Ly6G−Ly6C−F4/80+), monocyte-derived dendritic cells (DCs) (CD11b+CD11c+Ly6G−Ly6C+MHCII+), CD4+ T cells (CD3+CD4+), and CD8+ T cells (CD3+CD8+) by flow cytometry (see Figure S4 for gating scheme, two experiments; n = 8–10; two-tailed Mann-Whitney test; *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001; ns, not significant).
(E) At 3 and 7 dpi, ipsilateral ankles from WT and Mxra8 mice were harvested, homogenized, and the indicated cytokines or chemokines were measured (two experiments; n = 8–10, mean ± SD; two-way ANOVA with Sidak’s test; *p < 0.05; **p < 0.01; ****p < 0.0001; ns, not significant).
See also Figures S4 and S5.
Figure 7.Loss- and Gain-of-Function Effects of Mxra8 in Mice and Drosophila
(A) Structural representation of the CHIKV E2-D71 residue (red) on the cryoelectron microscopy (cryo-EM) model of Mxra8 bound to CHIKV (PDB 6NK6). Color scheme: Mxra8, purple; CHIKV E2, cyan; and CHIKV E1, gray. Inset: magnified view of the Mxra8-CHIKV E2-D71 interface.
(B) Loss of binding to Mxra8 by D71A mutation in CHIKV. WT and D71A CHIKV were captured with mouse CHK-152 (anti-E2) and CHK-166 mAb (anti-E1). After washing, Mxra8-Fc(human IgG1 Fc)was added and binding was measured. Equivalent amounts of WT and D71A CHIKV were captured on the microtiter plate as determined by the binding of humanized CHK-152. Humanized E16 (anti-West Nile virus [WNV] E) served as a negative control. Results are the mean of three experiments performed in triplicate (Mann-Whitney test: ****p < 0.0001).
(C) WT and Mxra8 mice were inoculated subcutaneously in the foot with 103 FFU of CHIKV-AF15561 (WT or D71A mutant). At 3 dpi, tissues were harvested for virus titration by FFU assay(two experiments; n = 8; two-tailed Mann-Whitney test; *p < 0.05, **p < 0.01, and ***p < 0.001; ns, not significant).
(D–F) Transgenic flies expressing mouse Mxra8 have increased susceptibility to CHIKV infection.(D) Flies of the indicated genotypes were analyzed for the ectopic expression of Mxra8 by western blotting. (E) The indicated flies were either uninfected or challenged with CHIKV (strain 181/25) and monitored daily for mortality. Data are pooled from three experiments and the number of flies are indicated (log rank test; **p < 0.01). (F) Groups of 15 flies of the indicated genotype were inoculated with CHIKV, and total RNA was collected at 7 dpi. Viral RNA was quantified by qRT-PCR, normalized to the housekeeping gene rp49, and shown relative to control (Act > +). Means ± SEMs are shown for four experiments (unpaired t test; *p < 0.05).
KEY RESOURCES TABLE
| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---|---|---|
| Antibodies | ||
| Anti-Mxra8 1G11.E6 | N/A | |
| Anti-Mxra8 3G2.F5 | N/A | |
| Anti-Mxra8 7F1.D8 | N/A | |
| Anti-Mxra8 9G2.D6 | N/A | |
| Armenian Hamster IgG Isotype Control | Bio X Cell | BE0260 |
| CHK-152 | N/A | |
| CHK-166 | N/A | |
| Humanized CHK-152 | N/A | |
| Humanized CHK-166 | N/A | |
| Humanized E16 | N/A | |
| Peroxidase AffiniPure Goat Anti-Human IgG (H+L) | Jackson ImmunoResearch | 109-035-088 |
| Peroxidase AffiniPure Goat Anti-Armenian Hamster IgG (H+L) | Jackson ImmunoResearch | 127-035-160 |
| Alexa Fluor 647 Goat Anti-Armenian Hamster IgG H&L | Abcam | ab173004 |
| Anti-Mouse CD16/32 Antibody | BioLegend | 101301 |
| PE/Dazzle 594 Anti-Mouse/Human CD11b Antibody | BioLegend | 101256 |
| PerCP/Cy5.5 Anti-Mouse Ly-6G Antibody | BioLegend | 127616 |
| Pacific Blue Anti-Mouse Ly-6C Antibody | BioLegend | 128014 |
| APC F4/80 Monoclonal Antibody (BM8) | Thermo Fisher | 17-4801-82 |
| PE-Cy7 Hamster Anti-Mouse CD11c Antibody | BD Biosciences | 558079 |
| Alexa Fluor 700 Anti-Mouse I-A/I-E Antibody | BioLegend | 107622 |
| PE Anti-Mouse NK-1.1 Antibody | BioLegend | 108708 |
| BUV737 Rat Anti-Mouse CD3 Antibody | BD Biosciences | 564380 |
| PerCP/Cyanine5.5 Anti-Mouse CD8a Antibody | BioLegend | 100734 |
| Brilliant Violet 785 Anti-Mouse CD4 Antibody | BioLegend | 100552 |
| Brilliant Violet 711 Anti-Mouse/Human CD45R/B220 Antibody | BioLegend | 103255 |
| Bacterial and Virus Strains | ||
| Chikungunya virus (strain LR 2006) | GenBank Accession No: | |
| Chikungunya virus (strain AF15561) | GenBank Accession No: | |
| Chikungunya virus E2-D71A mutant (strain AF15561) | This study | N/A |
| Chikungunya virus (strain 181/25) | GenBank Accession No: | |
| Ross River virus (strain T48) | World Reference Center for Emerging Viruses and Arboviruses | GenBank Accession number |
| Mayaro virus (strain BeH407) | World Reference Center for Emerging Viruses and Arboviruses | GenBank Accession number |
| O’nyong nyong virus (strain MP30) | World Reference Center for Emerging Viruses and Arboviruses | GenBank Accession number |
| Chemicals, Peptides, and Recombinant Proteins | ||
| Mammalian-expressed, codon-optimized mouse Mxra8 fused to human IgG1 Fc region | This study | N/A |
| Fixable Viability Dye eFluor 506 | eBioscience | 65-0866-14 |
| Collagenase | Sigma-Aldrich | C0130 |
| Deoxyribonuclease I | Sigma-Aldrich | D5025 |
| Critical Commercial Assays | ||
| MEGAscript T7 Transcription Kit | Thermo Fisher | AM1334 |
| MEGAclear Transcription Clean-Up Kit | Thermo Fisher | AM1908 |
| mMESSAGE mMACHINE SP6 Transcription Kit | Thermo Fisher | AM1340 |
| In-Fusion HD Cloning Plus | Takara | 638910 |
| RNAscope 2.5 HD Assay (Brown Kit) | Advanced Cell Diagnostics | 322310 |
| RNAscope 2.5 HD Assay (Red Kit) | Advanced Cell Diagnostics | 322360 |
| TaqMan RNA-to-Ct 1-Step Kit | Thermo Fisher | 4392938 |
| Bio-Plex Pro Mouse Cytokine 23-plex Assay Kit | Bio-Rad | m60009rdpd |
| Deposited Data | ||
| X-ray crystal structure of murine Mxra8 | PDB 6NK3 | |
| Electron Cryo-Microscopy of Chikungunya VLP in complex with mouse Mxra8 receptor | PDB 6NK6; EMD-9394 | |
| Experimental Models: Cell Lines | ||
| BHK-21 | ATCC | CCL-10 |
| Vero | ATCC | CCL-81 |
| C57BL/6J primary MEF | This study | N/A |
| C57BL/6J Mxra8Δ8/Δ8 primary MEF | This study | N/A |
| C57BL/6J Mxra8Δ97/Δ97 primary MEF | This study | N/A |
| Experimental Models: Organisms/Strains | ||
| Mouse: C57BL/6J | The Jackson Laboratory | 000664 |
| Mouse: C57BL/6J Mxra8+/Δ8 | This study | N/A |
| Mouse: C57BL/6J Mxra8Δ8/Δ8 | This study | N/A |
| Mouse: C57BL/6J Mxra8Δ97/Δ97 | This study | N/A |
| Bloomington Drosophila Stock Center | BDSC:4414; FlyBase: FBst0004414 | |
| Rainbow Transgenic Flies; This study | N/A | |
| Oligonucleotides | ||
| Mxra8_sgRNA-1: 5′-GGAAGACTCGGCGCT CGTGG-3′ | Genome Engineering and iPSC Center, Washington University in St. Louis | N/A |
| Mxra8_sgRNA-2: 5′-CTGTGACCAGACCCA TTGCC-3′ | Genome Engineering and iPSC Center, Washington University in St. Louis | N/A |
| CHIKV FOR: GGCAGTGGTCCCAGATAATTCAAG | This study | N/A |
| CHIKV FOR: ACTGTCTAGATCCACCCCATACATG | This study | |
| Drosophila rp49 FOR: AAGAAGCGCACCAAACACTTCATC | N/A | |
| Drosophila rp49 REV: TCTGTTGTCGATACCCTTCGGCTT | N/A | |
| CHK181/AF Fwd: 5′-TCGACGCGCCATCTTTAA-3′ | IDT | N/A |
| CHK181/AF Rev: 5′-ATCGAATGCACCGCACACT-3′ | IDT | N/A |
| CHK181/AF Probe: 5′-/56-FAM/ACCAGCCTG/ZEN/CACCCACTCCTCAGAC/3IABkFQ/-3′ | IDT | N/A |
| GAPDH TaqMan Primer/Probe set | IDT | Mm.PT.39a.1 |
| Mxra8 TaqMan Primer/Probe set | IDT | Mm.PT.58.42796673 |
| CHIKV RNA ISH probe | Advanced Cell Diagnostics | 481891 |
| Mxra8 RNA ISH probe | Advanced Cell Diagnostics | 520711 |
| Control RNA ISH probe | Advanced Cell Diagnostics | 320751 |
| Recombinant DNA | ||
| pUASTattB vector | N/A | |
| Codon-optimized mouse Mxra8 cloned into pUASTattB vector | This study | N/A |
| CHIKV AF15561 plasmid | ||
| CHIKV AF15561 E2-D71A plasmid | This study | N/A |
| Codon-optimized mouse Mxra8 and human IgG1 Fc cloned into pCDNA3.4 vector | This study | N/A |
| Software and Algorithms | ||
| FlowJo | FlowJo, LLC | Version 10 |
| PyMOL | Schrodinger | Version 2.1.0 |
| GraphPad Prism | GraphPad | Version 8.1.1 |